CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

Pharmacogenomics

Volumn 8, Issue 9, 2007, Pages 1199-1210

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Shirai, Naohito ^a   Ishizaki, Takashi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2C19; GERD; Helicobacter pylori; Intermediate metabolizer; Pharmacogenomics; Poor metabolizer; Proton pump inhibitor; Rapid metabolizer

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RNA 23S;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ERADICATION THERAPY; ETHNIC DIFFERENCE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER METABOLISM; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; SINGLE DRUG DOSE; STOMACH PH; THERAPY RESISTANCE; TREATMENT DURATION; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHARMACOGENETICS;

HELICOBACTER PYLORI;

EID: 35348844071     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.9.1199     Document Type: Review

References (76)

1. Blum RA: Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am. J. Health Syst. Pharm. 53(12), 1401-1415 (1996).
2. Lockhart SP: Clinical review of lansoprazole. Br. J. Clin. Pract. 75(Suppl.), 48-55 (1994).
3. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 54(3), 473-500 (1997).
4. Inatomi N, Nagaya H. Takami K, Shino A, Satoh H: Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn. J. Pharmacol. 55(4), 437-451 (1991).
5. Carswell CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs 61(15), 2327-2356 (2001).
6. Goldstein JL, Huang B, Amer F, Christopoulos NG: Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post hoc subanalysis. Clin. Ther. 26(10), 1637-1643 (2004).
7. Unge P: Review of Helicobacter pylori eradication regimens. Scand. J. Gastroenterol. 215(Suppl.), 74-81 (1996).
8. Asaka M, Sugiyama T, Kato M et al.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6(3), 254-261 (2001).
9. Furuta T, Futami H, Arai H, Hanai H, Kaneko E: Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J. Clin. Gastroenterol. 20(Suppl. 2), S107-S111 (1995).
10. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L: Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12(4), 415-416 (1990).
11. Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2(1), 25-31 (1992).
12. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4 -hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 262(3), 1195-1202 (1992).
13. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277(2), 805-816 (1996).
14. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J. Pharmacol. Exp. Ther. 283(2), 434-442 (1997).
15. Ishizaki T, Sohn DR, Kobayashi K et al.: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit. 16(2), 214-215 (1994).
16. Xiao ZS, Goldstein JA, Xie HG et al.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281(1), 604-609 (1997).
17. Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ: Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br. J. Clin. Pharmacol. 48(3), 402-408 (1999).
18. Marinac JS, Balian JD, Foxworth JW et al.: Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin. Pharmacol. Ther. 60(2), 138-144 (1996).
19. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57(6), 656-661 (1995).
20. de Morals SM, Goldstein JA, Xie HG et al.: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. 58(4), 404-411 (1995).
21. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60(6), 661-666 (1996).
22. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6(6), 547-551 (1996).
23. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA. Wood AJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9(5), 539-549 (1999).
24. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46(4), 594-598 (1994).
25. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephepytoin metabolism in humans. J. Biol. Chem. 269(22), 15419-15422 (1994).
26. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006).
27. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Sluda A, Starzynska T, Drozdzik M: Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin. Pharmacol. 62(10), 877-880 (2006).
28. Furuta T, Ohashi K, Kosuge K et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65(5), 552-561 (1999).
29. Saitoh T, Fukushima Y, Otsuka H et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 16(10), 1811-1817 (2002).
30. Shirai N, Furuta T, Moriyama Y et al.: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 15(12), 1929-1937 (2001).
31. Shirai N, Furuta T, Xiao F et al.: Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment. Pharmacol. Ther. 16(4), 837-846 (2002).
32. Sugimoto M, Furuta T, Shirai N et al.: Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 76(4), 290-301 (2004).
33. Kirsch C, Kuhlisch E, Lindner F et al.: influence of Cytochrome P450 2C19 polymorphism on intragastric acidity during treatment with high-dose esomeprazole and pantoprazole. Gastroenterology 132 (Suppl. 2) (4), A-607 (2007).
34. Nebel OT, Fornes MF, Castell DO: Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am. J. Dig. Dis. 21(11), 953-956 (1976).
35. Bardhan KD, Hawkey CJ, Long RG et al.: Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment. Pharmacol. Ther. 9(2), 145-151 (1995).
36. Bardhan KD: The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 9(Suppl. 1), 15-25 (1995).
37. Kirchgatterer A, Aschl G, Hinterreiter M, Stadler B, Knoflach P: Current concepts in therapy of reflux disease. Wien. Med. Wochenschr. 151(11-12), 266-269 (2001).
38. Furuta T, Shirai N, Watanabe F et al.: Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Cli. Pharmacol. Ther. 72(4), 453-460 (2002).
39. Kawamura M, Ohara S, Kolke T et al.: The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 17(7), 965-973 (2003).
40. Peghini PL, Katz PO, Bracy NA, Casten DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 93(5), 763-767 (1998).
41. Adachi K, Fujishiro, H, Katsube T et al.: Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol. Hepatol. 16(11), 1191-1196 (2001).
42. Klinkenberg-Knol EC, Meuwissen SG: Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment. Pharmacol. Ther. 4(5), 485-495 (1990).
43. Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. 98(3), 545-550 (2003).
44. Furuta T, Shirai N, Xiao F. Ohashi K, Ishizaki T: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 70(5), 484-492 (2001).
45. Xue S, Katz PO, Banerjee P, Tutulan R, Castell DO: Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 15(9), 1351-1356 (2001).
46. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115(6), 1335-1339 (1998).
47. Kinoshita Y, Adachi K, Fujishiro, H: Therapeutic approaches to reflux disease, focusing on acid secretion. J Gastroenterol. 38 (Suppl. 15), 13-19 (2003).
48. Blaser MJ: Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastronterology 102(2), 720-727 (1992).
49. Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N. Tauxe RV: Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1), 41-46 (1992).
50. Wotherspoon AC: Helicobacter pylori infection and gastric lymphoma. Br. Med. Bull. 54(1), 79-85 (1998).
51. Uemura N, Okamoto S, Yamamoto S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J Med. 345(11), 784-789 (2001).
52. Grayson ML, Eliopoulos GM. Ferraro MJ, Moellering RC Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8(10), 888-889 (1989)
53. Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 43 (Suppl. 1), S56-S60 (1908).
54. Scott DR, Weeks D, Hong C, Postius S, Melchers K, Sachs G: The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 114(1), 58-70 (1998).
55. Goddard AF, Jessa MJ, Barrett DA et al.: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111(2), 358-367 (1996).
56. Midolo PD, Turnidge JD, Lambert JR, Bell JM: Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob. Agents Chemother. 40(6), 1531-1533 (1996).
57. Furuta T, Ohashi K, Kamata T et al.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129(12), 1027-1030 (1998).
58. Andersson T. Miners JO, Veronese ME, Birkett DJ: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J Clin. Pharmacol. 37(6), 597-604 (1994).
59. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Oueuet D: Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos. 25(5), 623-630 (1997).
60. Furuta T, Ohashi K, Kobayashi K et al.: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther. 66(3), 265-274 (1999).
61. Furuta T, Shirai N, Takashima M et al.: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69(3), 158-168 (2001).
62. Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A. Kuriyama M: Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori Infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig. Liver Dis. 33(8), 671-675 (2001).
63. Inaba T, Mizuno M, Kawai K et al.: Randomized open trial for comparison of proton pump inhibitors for triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol. Hepatol. 17(7), 748-753 (2002).
64. Versalovic J, Osato MS, Spakovsky K et al.: Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40(2), 285-286 (1997).
65. Stone GG, Shortridge D. Versalovic J et al.: A PCR-oligonuleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents Chemother. 41(3), 712-714 (1997).
66. Menard A, Santos A, Megraud F, Oleastro M: PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob. Agents Chemother. 46(4), 1156-1157 (2002).
67. Furuta T, Sagehishi Y, Shirai N et al: Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin. Gastroenterol. Hepatol. 3(6), 564-573 (2005).
68. Adamek RJ, Suerbaum S. Pfaffenbach B, Opferkuch W: Primary and acquired Helicabacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am. J. Gastroenterol. 93(3), 386-389 (1998).
69. Bayerdorffer E, Miehlke S. Mannes GA et al.: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108(5); 1412-1417 (1995).
70. Furuta T, Shirai N, Xiao F et al.: High-dose rabeprazole/ amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50(54), 2274-2278 (2003).
71. Furuta T, Shirai N, Takashima M et al..: Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11(4), 341-348 (2001).
72. Miehlke S, Kirsch C, Schneider-Brachert W et al.: A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 8(4), 310-319 (2003).
73. Furuta T, Shirai N, Kodaira M et al.: pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther. 81(4), 521-528 (2007).
74. Tanigawara Y, Aoyama N, Kita T et al.: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66(5), 528-534 (1999).
75. Sapone A, Vaira D, Trespidi S et al.: The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am. J. Gastroenterol. 98(5), 1010-1015 (2003).
76. Shirai N, Sugimoto M. Kodaira C et al.: Dual therapy with high doses of rabeprazolev and amoxicillin versus triple therapy with rabeprazole, amoxicillin and metronidazole as the rescue regimen for Helicobacter pylori infection after triple therapy. Eur. J. Clin Pharmacol. 63(8), 734-739 (2007).